Kit for detecting anti-atherosclerosis drugs in blood plasma through ultra-high performance liquid chromatography-tandem mass spectrometry

Abstract

The invention discloses a kit for detecting anti-atherosclerosis drugs in blood plasma through an ultra-high performance liquid chromatography-tandem mass spectrometry technology, and belongs to the technical field of blood plasma detection. The kit aims at common anti-atherosclerosis medicines such as atorvastatin, o-hydroxy atorvastatin, p-hydroxy atorvastatin, rosuvastatin and digoxin. The kitdisclosed by the invention adopts an LC-MS/MS method, can be used for detecting the anti-atherosclerosis drugs at one time, and can be used for simultaneously monitoring a target drug and a metabolite; the kit is high in sensitivity and good in accuracy, can be well applied to clinical application, and provides a reliable basis for combined medication research of the blood plasma atherosclerosis-resistant drug.

Description

technical field [0001] The invention belongs to the technical field of drug detection, and in particular relates to a kit for detecting anti-atherosclerotic drugs in plasma by using ultra-high performance liquid chromatography tandem mass spectrometry technology. Background technique [0002] According to the China Cardiovascular Disease Report, cardiovascular disease (CVD) is the leading cause of death among Chinese residents. Hypertension and hyperlipidemia often coexist and are the basis for the progression and development of cardiovascular disease. Hyperlipidemia is the main risk factor for the progression of atherosclerosis, and atherosclerosis can lead to some cardiovascular complications, such as coronary heart disease, ischemic cerebrovascular disease, peripheral vascular disease, ischemic cerebrovascular disease and Peripheral Vascular Disease. Hyperlipidemia refers to the increase of lipids including fat, fatty acid, cholesterol, cholesteryl ester, phospholipid a...

AI Technical Summary

Problems solved by technology

Digoxin is a cardiac glycoside widely used in the treatment of congestive heart failure. Its medicinal use was first proposed by Withering in 1785, but its therapeutic range is narrow (0.8-2.0ng / mL), adding digoxin Complexity of use, therefore, small changes in digoxin pharmacokinetics may lead to reduced therapeutic efficacy or potentially severe toxicity

[0006] At present, there have been reports on the detection of the concentration of anti-atherosclerotic drugs in plasma in the existing technology. For example, Chinese patent CN107102079A discloses a liquid chromatography-tandem mass spectrometry method for detecting atorvastatin and its metabolites in human plasma and clinical pharmacy. For research applications, three drugs can be detected at the same time, the sample volume needs to be 100 μL, and nitrogen blowing is required to concentrate, and the pre-treatment is complicated; in addition, there are literature reports for the detection of one or several statins, but the efficiency is relatively low The analysis time of a single sample is long, the sensitivity is low, the linear range is not suitable, the sample pretreatment is complicated, the injection volume is large, and the matrix effect interferes, etc.

Images